title: Expression of granulysin mRNA in the human megakaryoblastic leukemia cell line CMK.
abstract: Granulysin is a newly reported cytolytic molecule and colocalizes with perforin and granzymes in the granules of cytotoxic T lymphocytes (CTL) and natural killer (NK) cells. In this study, we found that the megakaryoblastic leukemia cell line CMK, established from a patient with Down's syndrome, expressed granulysin mRNA. CMK was positive for CD13 and CD41 and negative for CD56. CMK also expressed CD2 and CD7. However, no rearrangement of the T-cell receptor beta-chain gene, an early marker of T-cell lineage, was found in CMK cells. Thus, CMK is assumed to originate from the clonal evolution at the immature cell level. The expression of granulysin in CMK cells suggests that granulysin is occasionally present in immature multilineage cells or may be characteristic of leukemic cells obtained from Down's syndrome patients. CMK has been reported to be capable of differentiating to mature megakaryocytes and produce platelets with normal function. It therefore seems to be possible that granulysin is also present in normal platelets. Unfortunately, we were not able to obtain evidence that normal platelets contain granulysin mRNA and its antigen.
authors.affiliation: Department of Medical Technology, Faculty of Health Sciences, Kobe University School of Medicine, Kobe, Japan.
authors.forename: Noriko
authors.initials: N
authors.lastname: Kitamura
authors.forename: Masahiro
authors.initials: M
authors.lastname: Koshiba
authors.forename: Osamu
authors.initials: O
authors.lastname: Horie
authors.forename: Ryukichi
authors.initials: R
authors.lastname: Ryo
mesh_terms: D000945:Antigens, Differentiation, T-Lymphocyte / Q000096:biosynthesis / Q000235:genetics*; D001792:Blood Platelets / Q000378:metabolism; D002454:Cell Differentiation; D019070:Cell Lineage; D004314:Down Syndrome / Q000150:complications*; D015973:Gene Expression Regulation, Leukemic; D015333:Gene Rearrangement, beta-Chain T-Cell Antigen Receptor; D053804:Granzymes; D006801:Humans; D016130:Immunophenotyping; D020014:K562 Cells / Q000378:metabolism; D007947:Leukemia, Megakaryoblastic, Acute / Q000235:genetics*; D008214:Lymphocytes / Q000378:metabolism; D008562:Membrane Glycoproteins / Q000096:biosynthesis / Q000235:genetics; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics*; D014411:Neoplastic Stem Cells / Q000166:cytology / Q000378:metabolism; D054353:Perforin; D052899:Pore Forming Cytotoxic Proteins; D012333:RNA, Messenger / Q000096:biosynthesis*; D012334:RNA, Neoplasm / Q000096:biosynthesis*; D012697:Serine Endopeptidases / Q000096:biosynthesis / Q000235:genetics; D014407:Tumor Cells, Cultured / Q000378:metabolism
chemical_list: D000945:Antigens, Differentiation, T-Lymphocyte; C075005:GNLY protein, human; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; D052899:Pore Forming Cytotoxic Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D054353:Perforin; C509213:GZMB protein, human; D053804:Granzymes; D012697:Serine Endopeptidases